Acrux Limited soars: Is there time to catch the flight?

Acrux Limited (ASX: ACR) jumped more than 12% in trade this morning to $1.29 as investors conclude sales problems facing the company’s key testosterone therapy product, Axiron, may be short-term in nature.

Sales slumped after the U.S Food and Drug Administration (FDA) announced in January that it was looking into health concerns around testosterone therapy treatments such as those produced by Acrux. Testosterone therapy has long been known to carry certain health risks and products sold already carry labelling outlining the risks. The FDA has also said its current view remains that the health benefits outweigh the known risks, although it is yet to announce the results of its latest investigation.

Acrux has also been heavily short sold by speculators and the buying today may be a result of those speculators closing positions that are out of the money. Short selling is a high stakes game that can result in liberal amounts of egg on the face if sentiment or company news turns against those speculating on a falling share price.

The announcement of the FDA investigation and sales drop may indeed prove to be a short-term storm that blows over, as testosterone therapy to improve male energy levels or sex drives is a growth area with strong tailwinds. Sex sells and memories can be short, in which case Acrux may return to a growth trajectory yet.


Acrux remains a risky play with potentially high rewards. But there may be three even better ones for those chasing big profits.

Discover 3 high-risk/high-reward resources tips for your portfolio.  Just enter your email to get our FREE brand-new report -- "3 Tiny Resources Companies That Could Win Big" -- FREE!


Motley Fool contributor Tom Richardson owns shares in Acrux Limited. You can find him on Twitter @tommyr345

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.